Back to top
more

Edwards Lifesciences (EW)

(Real Time Quote from BATS)

$66.75 USD

66.75
3,261,118

+0.52 (0.79%)

Updated Nov 11, 2024 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Instruments

Zacks News

NuVasive Launches Breakthrough in MIS Surgery -- LessRay

NuVasive's latest LessRay system reduces radiation emission and exposure. The stock is likely to gain on number of vital developments despite a brief dull phase in between.

    Genomic Health Ties up With Biocartis, Boosts Oncotype DX

    Genomic Health's (GHDX) agreement with Biocartis will provide Genomic Health rights to develop and commercialize its Oncotype DX Breast Recurrence Score test on the Idylla platform.

      Fresenius Medical Opens Manufacturing Plant in Malaysia

      Fresenius Medical's (FMS) Malaysian plant will strengthen the company's presence in the rapidly-growing market.

        Amedisys Rides High on Strong Prospects Amid Margin Woes

        Strength in Hospice and Personal Care businesses are offsetting the weakness in Amedisys' (AMED) Home Health Medicare business.

          Medtronic's IN.PACT Admiral Approval in Japan Boosts APV Arm

          Medtronic's (MDT) receipt of Japanese regulatory approval for IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.

            IDEXX Laboratories Rides High on Strong CAG, Global Growth

            IDEXX (IDXX) rides high on balanced segmental growth with significant contributions from the Companion Animal Group business. Moreover, strong fundamentals buoy optimism.

              Medtronic Launches StealthStation Technology, Expands in ENT

              Medtronic (MDT) recently launched StealthStation ENT, which enables surgeons to gain better visualization.

                AmerisourceBergen's PharMEDium Slows Down, Competition Rife

                AmerisourceBergen Corporation's (ABC) expects tepid performance from PharMEDium due to pricing pressure in the generic drug space.

                  CVS Health Gains on Pharmacy Services, Retail Remains a Drag

                  CVS Health (CVS) benefits from strong Pharmacy Services numbers and continues to deliver solid PBM selling seasons. Retail performance stays sluggish on several headwinds.

                    Quotient Limited (QTNT) in Focus: Stock Moves 30.3% Higher

                    Quotient Limited (QTNT) saw its shares rise over 30% on the day.

                      Medtronic (MDT) Begins Product Recall, Diabetes Group a Drag

                      Medtronic (MDT) decides to recall specific lots of insulin pumps in peril. The devices appear to potentially over-deliver insulin exposing patients to chances of hypoglycemia.

                        Becton, Dickinson's (BCR) C.R. Bard Buyout Plans Bode Well

                        Becton, Dickinson and Company's (BDX) steady move toward the pending acquisition of C.R. Bard will lend it a leading position in the healthcare domain.

                          Why the Earnings Streak Will Continue for Edwards Lifesciences (EW)

                          Edwards Lifesciences (EW) can be a harbinger of out performance and a signal for a strong earnings profile on the back of its favorable Zacks rank and earnings ESP in the positive territory.

                            Zimmer Biomet (ZBH) Launches Persona Partial Knee System

                            Zimmer Biomet (ZBH) is constantly trying to turn its Knees business around. Keeping in line with the efforts, the company has launched Persona Partial Knee System.

                              Cooper Companies Buys Teva's PARAGARD Intrauterine Platform

                              Cooper Companies (COO) latest development is expected to fortify its foothold in the contraceptive device market. Margins are likely to improve within one year of the deal closure.

                                Henry Schein MicroMD Software Gets ONC-Health IT Certificate

                                Henry Schein's (HSIC) MicroMD receives ONC-Health IT Certificate from Drummond Group, boosting the company's technology and value-added service business.

                                  NuVasive Announces Vertera Spine Buyout, Boosts Implants Suite

                                  NuVasive (NUVA) to add three-dimensional porous interbody technology across polyetheretherketone (PEEK) material as well through the Vertera Spine buyout.

                                    Chemed Rides on VITAS Recovery, Robust Roto-Rooter Sales

                                    Chemed (CHE) steers growth with VITAs business' revival from struggle and Roto-Rooter's consistent rise on the back of core plumbing and drain cleaning service segments.

                                      NuVasive Grows in Pediatric Deformity With New FDA Approval

                                      NuVasive (NUVA) has progressed with its 'Embracing the Journey Together' program with the FDA nod to use the company's redesigned MAGEC system with its RELINE Small Stature system.

                                        Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?

                                        Abbott's (ABT) recent FDA approval for Full MagLev HeartMate 3 Left Ventricular Assist Device has boosted investor confidence.

                                          8 Factors That Make Thermo Fisher a Valuable Pick Right Now

                                          Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.

                                            Cooper to Benefit From Specialty Lenses Prospects Amid Woes

                                            The Cooper Companies' (COO) strong sales growth will continue to be aided by a leading position in the market of specialty lenses.

                                              Align Technology at 52-Week High: What's Driving the Stock?

                                              Align Technology's (ALGN) efforts to expand worldwide instil confidence in investors. The market is upbeat about the non-exclusive distribution agreement with Patterson Dental.

                                                Myriad Genetics Boosts myRisk Hereditary Cancer Test Suite

                                                Myriad Genetics (MYGN) introduces riskScore, a breast cancer prediction tool to broaden its myRisk hereditary cancer test offerings.

                                                  HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates

                                                  HealthEquity (HQY) delivered favorable results in the second quarter of fiscal 2018 on the back of revenue and margin expansion.